Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRISPR Therapeutics AGCRSP · Entity 3852 | Director · President | June 30, 2021 | July 01, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRISPR Therapeutics AG
Report date June 30, 2021 · Filed July 01, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 573,007 |
Reported balance
After 2021-06-30 transaction · row 1
1 source rowRow 1 · 2021-06-30 · Sale · Disposed 25,000 · Balance 573,007 F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2017 Filed May 4, 2017 21:44 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 13,191 | $1.81 | $23,875.71 |
DisclosureSEC source: 0000899243-17-011883 · doc4.xml · nonDerivative · entry 6 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,229,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2017 Filed May 4, 2017 21:44 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Options (Right to Buy) · Derivative | 20,269 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-011883 · doc4.xml · derivative · entry 9 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,900 Underlying: Common Shares · 20,269 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 share immediately vested on the grant date and the remaining 173,143 shares vest in 31 equal monthly installments thereafter. Read SEC document |
| May 03, 2017 Filed May 4, 2017 21:44 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,022 | $16.64 | $17,002.61 |
DisclosureSEC source: 0000899243-17-011883 · doc4.xml · nonDerivative · entry 5 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,215,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.51 to $16.84, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 03, 2017 Filed May 4, 2017 21:44 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 19,247 | $16.05 | $308,983.64 |
DisclosureSEC source: 0000899243-17-011883 · doc4.xml · nonDerivative · entry 4 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,216,027 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.51 to $16.45, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 03, 2017 Filed May 4, 2017 21:44 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 20,269 | $1.81 | $36,686.89 |
DisclosureSEC source: 0000899243-17-011883 · doc4.xml · nonDerivative · entry 3 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,235,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2017 Filed May 4, 2017 21:44 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Options (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-011883 · doc4.xml · derivative · entry 8 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,169 Underlying: Common Shares · 50,000 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 share immediately vested on the grant date and the remaining 173,143 shares vest in 31 equal monthly installments thereafter. Read SEC document |
| May 02, 2017 Filed May 4, 2017 21:44 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 15,924 | $16.53 | $263,236.46 |
DisclosureSEC source: 0000899243-17-011883 · doc4.xml · nonDerivative · entry 2 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,215,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.30 to $17.00, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 02, 2017 Filed May 4, 2017 21:44 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 15,924 | $1.81 | $28,822.44 |
DisclosureSEC source: 0000899243-17-011883 · doc4.xml · nonDerivative · entry 1 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,230,929 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 20, 2017 Filed Apr 21, 2017 20:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Options (Right to Buy) · Derivative | 2,294 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-010733 · doc4.xml · derivative · entry 7 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,093 Underlying: Common Shares · 2,294 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 share immediately vested on the grant date and the remaining 173,143 shares vest in 31 equal monthly installments thereafter. Read SEC document |
| April 20, 2017 Filed Apr 21, 2017 20:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 2,294 | $17.37 | $39,851.83 |
DisclosureSEC source: 0000899243-17-010733 · doc4.xml · nonDerivative · entry 5 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,215,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.20 to $17.53, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 20, 2017 Filed Apr 21, 2017 20:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 2,294 | $1.81 | $4,152.14 |
DisclosureSEC source: 0000899243-17-010733 · doc4.xml · nonDerivative · entry 4 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,217,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 20:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Options (Right to Buy) · Derivative | 47,706 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-010733 · doc4.xml · derivative · entry 6 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,387 Underlying: Common Shares · 47,706 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 share immediately vested on the grant date and the remaining 173,143 shares vest in 31 equal monthly installments thereafter. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 20:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 15,368 | $18.61 | $285,987.72 |
DisclosureSEC source: 0000899243-17-010733 · doc4.xml · nonDerivative · entry 3 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,215,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.06 to $19.05, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 20:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 32,338 | $17.57 | $568,078.41 |
DisclosureSEC source: 0000899243-17-010733 · doc4.xml · nonDerivative · entry 2 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,230,373 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.05 to $18.045, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 20:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 47,706 | $1.81 | $86,347.86 |
DisclosureSEC source: 0000899243-17-010733 · doc4.xml · nonDerivative · entry 1 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,262,711 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 18, 2016 Filed Oct 20, 2016 21:20 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0000899243-16-032076 · doc4.xml · derivative · entry 1 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Shares · 200,000 shares Expires 2026-10-18 F1 · derivative.exercise_date: This option was granted on October 18, 2016 with respect to 200,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning October 31, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.